Abstract
Russell Katz is the director of the Division of Neurology Products in the US FDA’s Center for Drug Evaluation and Research. Katz’s division is responsible for regulating research with investigational treatments for neurologic diseases, including epilepsy, as well as making decisions about which treatments should be approved. He has written and lectured extensively about all aspects of the development of treatments for neurologic diseases. Katz speaks to Laura Harvey at the journal, on the difficulties facing antiepilepsy drug trials today.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
